Factor V Leiden mutation enhances fibrin formation and dissolution in vivo in a human endotoxemia model

Blood

Volumn 116, Issue 5, 2010, Pages 801-805

  Elmas, Elif ^a   Suvajac, Nenad ^a   Jilma, Bernd ^b   Weiler, Hartmut ^c   Borggrefe, Martin ^a   Dempfle, Carl Erik ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ENDOTOXIN; FIBRIN; FIBRINOGEN; PLASMIN; PLASMIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 5; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PLASMIN PLASMIN INHIBITOR COMPLEX; PLASMIN-PLASMIN INHIBITOR COMPLEX; PLASMINOGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; FIBRIN FORMATION; FIBRINOLYSIS; GENE MUTATION; HEMOSTASIS; HETEROZYGOTE; HUMAN; IN VIVO STUDY; MALE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; BIOSYNTHESIS; BLOOD; ENZYME ACTIVATION; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SOLUBILITY; TIME;

ADULT; AGED; ALPHA-2-ANTIPLASMIN; ENDOTOXEMIA; ENZYME ACTIVATION; FACTOR V; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIN; FIBRINOLYSIS; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN; SOLUBILITY; TIME FACTORS; YOUNG ADULT;

EID: 77956285538     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-213215     Document Type: Article

References (27)

1. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64-67. (Pubitemid 24144355)
2. Dahlback B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995;74(1):139-148.
3. Dahlback B. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis. J Intern Med Suppl. 1997;740:1-8.
4. Lindqvist PG, Dahlback B. Carriership of Factor V Leiden and evolutionary selection advantage. Curr Med Chem. 2008;15(15):1541-1544.
5. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2(11):1924-1933.
6. Yan SB, Nelson DR. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med. 2004;32(5 Suppl):S239-S246.
7. Kerlin BA, Yan SB, Isermann BH, et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003;102(9):3085-3092.
8. Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M. Effect of the factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J. 1999;18(10):893-896. (Pubitemid 29487510)
9. Benfield TL, Dahl M, Nordestgaard BG, Tybjaerg-Hansen A. Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis. 2005;192(10):1851-1857.
10. Bruggemann LW, Schoenmakers SH, Groot AP, Reitsma PH, Spek CA. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med. 2006;34(8):2201-2206.
11. Pernerstorfer T, Hollenstein U, Hansen J, et al. Heparin blunts endotoxin-induced coagulation activation. Circulation. 1999;100(25):2485-2490.
12. Pernerstorfer T, Schmid R, Bieglmayer C, Eichler HG, Kapiotis S, Jilma B. Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial. Clin Pharmacol Ther. 1999;66(1):51-57. (Pubitemid 29350445)
13. Clauss A. Rapid physiological coagulation method in determination of fibrinogen [in German]. Acta Haematol. 1957;17(4):237-246.
14. Nakahara K, Kazahaya Y, Shintani Y, et al. Measurement of soluble fibrin monomer-fibrinogen complex in plasmas derived from patients with various underlying clinical situations. Thromb Haemost. 2003;89(5):832-836.
15. Suzuki A, Ebinuma H, Matsuo M, Miyazaki O, Yago H. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. Thromb Res. 2007;121(3):377-385.
16. Halvorsen S, Skjonsberg OH, Godal HC. The stimulatory effect of soluble fibrin on plasminogen activation by tissue plasminogen activator as studied by the Coa-set Fibrin Monomer test. Thromb Res. 1991;61(4):453-461.
17. Verheijen JH, Nieuwenhuizen W, Wijngaards G. Activation of plasminogen by tissue activator is increased specifically in the presence of certain soluble fibrin(ogen) fragments. Thromb Res. 1982;27(4):377-385.
18. Dempfle CE, Argiriou S, Kucher K, Muller-Peltzer H, Rubsamen K, Heene DL. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod. Blood. 2000;96(8):2793-2802.
19. Dempfle CE, Alesci S, Kucher K, Muller-Peltzer H, Rubsamen K, Borggrefe M. Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod. Thromb Res. 2001;104(6):433-438.
20. Pernerstorfer T, Hollenstein U, Hansen JB, et al. Lepirudin blunts endotoxin-induced coagulation activation. Blood. 2000;95(5):1729-1734. (Pubitemid 30120836)
21. Spiel AO, Mayr FB, Firbas C, Quehenberger P, Jilma B. Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost. 2006;4(2):411-416.
22. Asakura H, Ontachi Y, Mizutani T, et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med. 2001;29(6):1164-1168.
23. Asakura H, Sano Y, Yamazaki M, Morishita E, Miyamoto K, Nakao S. Role of fibrinolysis in tissue-factor-induced disseminated intravascular coagulation in rats-an effect of tranexamic acid. Haematologica. 2004;89(6):757-758.
24. Binder A, Endler G, Muller M, Mannhalter C, Zenz W. 4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. J Thromb Haemost. 2007;5(10):2049-2054.
25. Emonts M, de Bruijne EL, Guimaraes AH, et al. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost. 2008;6(2):268-276. (Pubitemid 351144609)
26. Gamper G, Oschatz E, Herkner H, et al. Sepsis-associated purpura fulminans in adults. Wien Klin Wochenschr. 2001;113(3-4):107-112.
27. Lasch HG, Heene DL, Huth K, Sandritter W. Pathophysiology, clinical manifestations and therapy of consumption-coagulopathy (" Verbrauchskoagulopathie"). Am J Cardiol. 1967;20(3):381-391.